KalVista Pharmaceuticals Inc (STU:4XC1)
€ 7.65 0 (0%) Market Cap: 418.37 Mil Enterprise Value: 294.15 Mil PE Ratio: 0 PB Ratio: 2.85 GF Score: 47/100

Kalvista Pharmaceuticals Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript

May 30, 2023 / 02:55PM GMT
Release Date Price: €8.8 (+0.57%)
Paul Matteis
Stifel Financial Corp. - Moderator

Great. Good morning, everybody. It's my pleasure to be moderating a chat with Andy Crockett, CEO of KalVista; Chris Yea, Chief Development Officer; and Ben Palleiko, Chief Financial Officer. We'll keep this more conversational, but maybe I'll kick it over to Andy to start, just to give a quick background on the company and an update on the 900 Phase 3 program and then we can get into more specifics. So Andy, thank you again, and please take it away.

Andy Crockett
Kalvista Pharmaceuticals, Inc. - CEO

Thanks, Paul, for having us. Good to be here with you.

Yes. So we're KalVista. We are focused on discovery and development of small molecule protease inhibitors. And our lead program is sebetralstat. Sebetralstat is a small molecule plasma kallikrein inhibitor for the treatment of on-demand attacks of HAE and is currently in a Phase 3 clinical trial. Sebetralstat that had some really nice Phase 2 clinical data where we met all of our primary secondary endpoints and showed that it is a drug that is rapidly

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot